REFERENCES


generation drug eluting stents, and second generation drug eluting stents. Results from a registry of

followed by 6- versus 12- month dual antiplatelet therapy: the SECURITY randomized clinical trial. *J
Am Coll Cardiol* 2014;64:2086-2097.

27. Gilard M, Barragan P, Noryani AAL, et al. 6- versus 24 month dual antiplatelet therapy after
implantation of drug-eluting stents in patients nonresistant to aspirin. The randomized, multicenter

28. Mauri L, Kereiakes DJ, Yeh RW, et al. Twelve or 30 months of dual antiplatelet therapy after drug

discontinuation of thienopyridine therapy after drug-eluting stent placement results from the

30. Park CB, Park HK. Identification of independent risk factors for restenosis following bare-metal

31. Yeh RW, Normand SLT, Wolf RE, et al. Predicting the restenosis benefit of drug-eluting versus


34. Siller-Matula JM, Trenk D, Schror K, et al; EPA (European Platelet Academy). Response

on platelet function: magnitude of platelet inhibition is related to active metabolite formation. *Am


